Success Metrics

Clinical Success Rate
85.5%

Based on 47 completed trials

Completion Rate
85%(47/55)
Active Trials
1(2%)
Results Posted
53%(25 trials)
Terminated
8(13%)

Phase Distribution

Ph early_phase_1
1
2%
Ph phase_2
31
51%
Ph not_applicable
1
2%
Ph phase_1
21
34%
Ph phase_3
5
8%

Phase Distribution

22

Early Stage

31

Mid Stage

5

Late Stage

Phase Distribution59 total trials
Early Phase 1First-in-human
1(1.7%)
Phase 1Safety & dosage
21(35.6%)
Phase 2Efficacy & side effects
31(52.5%)
Phase 3Large-scale testing
5(8.5%)
N/ANon-phased studies
1(1.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

82.5%

47 of 57 finished

Non-Completion Rate

17.5%

10 ended early

Currently Active

1

trials recruiting

Total Trials

61

all time

Status Distribution
Active(1)
Completed(47)
Terminated(10)
Other(3)

Detailed Status

Completed47
Terminated8
unknown3
Withdrawn2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
61
Active
1
Success Rate
85.5%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (1.7%)
Phase 121 (35.6%)
Phase 231 (52.5%)
Phase 35 (8.5%)
N/A1 (1.7%)

Trials by Status

completed4777%
unknown35%
active_not_recruiting12%
withdrawn23%
terminated813%

Recent Activity

1 active trials
Showing 5 of 61
active_not_recruitingphase_1

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

NCT01947023
terminatedphase_2

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

NCT01382706
completedphase_3

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

NCT00770809
completedphase_3

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

NCT00667251
completedphase_1

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

NCT02101905
View all 61 trials

Clinical Trials (61)

Showing 20 of 61 trialsScroll for more
NCT01947023Phase 1

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

Active Not Recruiting
NCT01382706Phase 2

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Terminated
NCT00770809Phase 3

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Completed
NCT00667251Phase 3

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Completed
NCT02101905Phase 1

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Completed
NCT00424164Phase 1

Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer

Completed
NCT01622868Phase 2

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

Completed
NCT01873833Phase 2

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

Terminated
NCT00436566Phase 2

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Completed
NCT00085020Phase 1

GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

Completed
NCT00684983Phase 2

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Completed
NCT01044433Phase 2

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

Completed
NCT00331630Early Phase 1

Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Completed
NCT00390455Phase 3

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Completed
NCT01783756Phase 1

Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis

Completed
NCT00820872Phase 2

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

Completed
NCT00096447Phase 2

Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Completed
NCT00113373Phase 2

Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

Completed
NCT01434303Phase 1

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

Completed
NCT01104571Phase 3

Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
61